Teijin Limited

Katsuhiko Tomibe

Yasuhiko Masuho

Sachio Ishimoto

Takashi Kawamura

Toru Sugano

Yoh-Ichi Matsumoto

Shuzo Sawada

Kimihiko Matsuzawa

Kazuo Satake

Tsuneo Watanabe

P. aeruginosa E87Ag antigen comprising polysaccharide fraction with molecular weight of about 27,000 which is contained in lipopolysaccharide of P. aeruginosa; anti-P. aeruginosa human or mouse monoclonal antibody which recognizes said E87Ag antigen; and mouse-human or mouse-mouse hybridoma which produces said monoclonal antibody. The monoclonal antibody can be used for making diagnosis and therapy of infections with P. aeruginosa.

E87Ag antigens of Pseudomonas aeruginosa and monoclonal antibodies

Mouse-human hybridoma which produces antivirus-human antibody, process

Novel immunoglobulin derivatives which are characterized in that in which the interchain disulfide bonds of immunoglobulin are predominantly cleaved, on the average 3 to 5 of the interchain disulfide bonds or the inter- and intra-chain disulfide bonds being cleaved, and so produced sulfur atoms (S-) are S-sulfonated (--S-SO.sub.3). The above immunoglobulin derivatives are prepared by reacting native immunoglobulin with A. a compound capable of forming tetrathionate ion, and B. a compound capable of forming in water, sulfite ion whereby cleaving on the average 3 to 5 inter-chain disulfide bonds, or inter- and intra-chain disulfide bonds, of the native immunoglobulin, and S-sulfonating (S-SO.sub.3) the so formed sulfur atoms. This invention also provides a water-soluble composition for injection containing said immunoglobulin derivative having the titre of anti-diphtheria of at least 1.0 I.U./ml at its concentration of 10.0% by weight, and a pharmaceutically-acceptable solubilizing agent for said immunoglobulin derivative.

Novel immunoglobulin derivatives and process for the preparation thereof

Growing community of inventors

Tokyo, Japan

Katsuhiko Tomibe